The short version of Certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-11. Anything still debated is marked as such rather than presented as settled.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Calculated for the free peptide |
| Molecular weight | About 751.9 g/mol | Derived from the sequence |
| Appearance | White to off-white powder | Typical lyophilised form |
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
The history of anorexia begins with descriptions of religious fasting dating from the Hellenistic era and continuing into the medieval period. The medieval practice of self-starvation by women, including some young women, in the name of religious piety and purity is sometimes referred to as anorexia mirabilis. The earliest medical descriptions of anorexic illnesses are generally credited to English physician Richard Morton in 1689. Etymologically, anorexia is a term of Greek origin: an- (ἀν-, prefix denoting negation) and orexis (ὄρεξις, "appetite"), translating literally to "a loss of appetite". In and of itself, this term does not have a harmful connotation, e.g., exercise-induced anorexia simply means that hunger is naturally suppressed during and after sufficiently intense exercise sessions. It is the adjective nervosa that indicates the functional and non-organic nature of the disorder, but this adjective is also often omitted when the context is clear. Despite the literal translation of anorexia, the feeling of hunger in anorexia nervosa is frequently present and the pathological control of this instinct is a source of satisfaction for the patients. The term "anorexia nervosa" was coined in 1873 by Sir William Gull, one of Queen Victoria's personal physicians. Gull published a seminal paper providing a number of detailed case descriptions of patients with anorexia nervosa. In the same year, French physician Ernest-Charles Lasègue similarly published details of a number of cases in a paper entitled De l'Anorexie hystérique.
==== Eliminated in primary ==== Daniel Betts, attorney and nominee for Travis County district attorney in 2024 Jason Cahill, businessman Jacques DuBose, former Boerne city councilman Zeke Enriquez, U.S. Marine Corps veteran (previously ran in the 23rd district) Weston Martinez, businessman Paul Rojas, engineer Heather Tessmer, attorney Trey Trainor, former commissioner from the Federal Election Commission (2020–2025) Peggy Wardlaw, engineer and candidate for this district in 2018 Michael Wheeler, senior advisor to the Small Business Administration and former chair of the Kendall County Republican party
Renal failure occurs when the kidneys fail to adequately filter waste from the blood and can lead to death if not treated with dialysis or kidney transplantation. Cancer can affect the bladder, kidneys, urethra and ureters, with the latter two being far more rare.
=== Off-label drugs === α2-Adrenergic receptor agonists (e.g., clonidine, tizanidine) Acetaminophen (paracetamol) Adenosine receptor antagonists (e.g., caffeine) Angiotensin-converting-enzyme inhibitors (ACE inhibitors) (e.g., lisinopril) Angiotensin receptor antagonists (e.g., candesartan, telmisartan) Antipsychotics and related (e.g., prochlorperazine, metoclopramide, haloperidol, promethazine, chlorpromazine) Anticonvulsants (e.g., valproic acid) Barbiturates (e.g., butalbital, proxibarbital) Beta blockers (β-adrenergic receptor antagonists) (e.g., propranolol, metoprolol, nadolol, timolol, atenolol) Calcium channel blockers (e.g., verapamil, nimodipine, nifedipine, diltiazem) Cannabinoids (cannabinoid receptor agonists) (e.g., cannabis, tetrahydrocannabinol (THC)) Corticosteroids (e.g., dexamethasone, prednisone) Ergoline monoamine receptor modulators (e.g., ergotamine, methylergometrine, methysergide, dihydroergocryptine, bromocriptine, lisuride) Estrogens (estrogen receptor agonists) (e.g., estradiol, ethinylestradiol) Gabapentinoids (α2δ subunit-containing volate-gated calcium channel ligands) (e.g., gabapentin, pregabalin) Melatonin Nonsteroidal anti-inflammatory drugs (NSAIDs; COX inhibitors) (e.g., ibuprofen, aspirin, naproxen, diclofenac, ketorolac, ketoprofen) Opioids (μ-opioid receptor agonists) (e.g., morphine, codeine, oxycodone, hydrocodone) Progestogens (progesterone receptor agonists) (e.g., progesterone, medroxyprogesterone acetate) Propofol Serotonergic psychedelics (e.g., psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine (DMT)) Serotonin receptor antagonists (e.g., methysergide, pizotifen, cyproheptadine) Sodium channel blockers (e.g., lidocaine) Tetracyclic antidepressants (TeCAs) (e.g., mianserin, mirtazapine) Tricyclic antidepressants (TCAs) (e.g., amitriptyline, nortriptyline, imipramine)
==== Enolisation ==== Enolisation of RuBP is the conversion of the keto tautomer of RuBP to an enediol(ate). Enolisation is initiated by deprotonation at C3. The enzyme base in this step has been debated, but the steric constraints observed in crystal structures have made Lys210 the most likely candidate. Specifically, the carbamate oxygen on Lys210 that is not coordinated with the Mg ion deprotonates the C3 carbon of RuBP to form a 2,3-enediolate.
Sources: en.wikipedia.org
In contrast, other proteins have evolved to bind to particular DNA sequences. The most intensively studied of these are the various transcription factors, which are proteins that regulate transcription. Each transcription factor binds to one particular set of DNA sequences and activates or inhibits the transcription of genes that have these sequences close to their promoters. The transcription factors do this in two ways. Firstly, they can bind the RNA polymerase responsible for transcription, either directly or through other mediator proteins; this locates the polymerase at the promoter and allows it to begin transcription. Alternatively, transcription factors can bind enzymes that modify the histones at the promoter. This changes the accessibility of the DNA template to the polymerase. As these DNA targets can occur throughout an organism's genome, changes in the activity of one type of transcription factor can affect thousands of genes. Consequently, these proteins are often the targets of the signal transduction processes that control responses to environmental changes or cellular differentiation and development. The specificity of these transcription factors' interactions with DNA come from the proteins making multiple contacts to the edges of the DNA bases, allowing them to "read" the DNA sequence. Most of these base-interactions are made in the major groove, where the bases are most accessible.
Insect-resistant crops have proven to lower pesticide usage, therefore reducing the environmental impact of pesticides as a whole. However, opponents have objected to GM crops per se on several grounds, including environmental concerns, whether food produced from GM crops is safe, whether GM crops are needed to address the world's food needs, and economic concerns raised by the fact these organisms are subject to intellectual property law. Biotechnology has several applications in the realm of food security. Crops like Golden rice are engineered to have higher nutritional content, and there is potential for food products with longer shelf lives. Though not a form of agricultural biotechnology, vaccines can help prevent diseases found in animal agriculture. Additionally, agricultural biotechnology can expedite breeding processes in order to yield faster results and provide greater quantities of food. Transgenic biofortification in cereals has been considered as a promising method to combat malnutrition in India and other countries.
== Discovery == Asprosin was first identified by Dr. Atul Chopra and colleagues at Baylor College of Medicine during their study of Marfanoid–progeroid–lipodystrophy syndrome (MPL), also known as neonatal progeroid syndrome (NPS), a rare genetic disorder caused by mutations in the FBN1 gene. These mutations produce truncated profibrillin-1 protein, resulting in two key effects: the production of a mutant fibrillin-1 protein and significantly reduced plasma asprosin levels due to a dominant-negative mechanism. The discovery of asprosin's role as a fasting-induced glucogenic hormone, stimulating hepatic glucose release, stemmed from the observation of low plasma insulin levels in the two patients. A subsequent study by Chopra and colleagues investigated the patients' extreme thinness and abnormally low appetite, uncovering asprosin's additional role as an orexigenic hormone that regulates appetite through hypothalamic neurons. To further investigate the condition, Chopra and colleagues developed a mouse model carrying the MPL mutation, which faithfully phenocopied the human disorder. These mice exhibited the same features as the patients, including low plasma asprosin levels, extreme thinness, reduced appetite, and resistance to diet-induced obesity and diabetes. This model confirmed the role of asprosin in regulating appetite and body weight through its orexigenic effects on hypothalamic neurons and demonstrated its broader implications in metabolic health.
According to the National Drug Intelligence Center, Mexican cartels are the predominant smugglers and wholesale distributors of South American cocaine and Mexico-produced cannabis, methamphetamine, and heroin. The U.S. State Department estimates that 90 percent of cocaine entering the United States is produced in Colombia, followed by Bolivia and Peru, and that the main transit route is through Mexico. Mexican cartels control large swaths of territory, and most of the illegal drugs coming into the U.S., employing land routes, maritime shipments, smuggling tunnels, and other concealment methods. Cartels have waged violent turf battles over control of key smuggling corridors from Matamoros to Tijuana. Cartels operate clandestine laboratories that process precursor chemicals into synthetic drugs. These chemicals are primarily imported from Asia, especially China and India, and are used to manufacture methamphetamine and fentanyl in large quantities. Since the 2010s, fentanyl has become one of the most profitable components of cartel operations due to its low production cost and high potency. Although Mexico accounts for only a small share of worldwide heroin production, it supplies a large share of the heroin distributed in the United States. Since the 2000s, Mexican cartels have profited from marijuana cultivation in remote U.S. forests. A 2018 study found that the reduction in drugs from Colombia contributed to Mexican drug violence.
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.
Selank is a synthetic analogue built on the tuftsin tetrapeptide Thr-Lys-Pro-Arg. Extra proline residues were added to the C-terminus during design work. That modification is intended to make the peptide less vulnerable to rapid enzymatic degradation.
Transliteration from Russian produces variant spellings such as Selanc. Many suppliers avoid the trade-style name entirely and list the peptide sequence. Comparing sequences rather than names is the reliable way to confirm two entries describe the same molecule.
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.